Angle PLC Announces Parsortix Enables Gene Expression Analysis in mPCa

PARSORTIX SYSTEM ENABLES GENE EXPRESSION ANALYSIS IN METASTATIC PROSTATE CANCER PATIENTS
Parsortix able to isolate CTCs in 80% of patients providing access to tumour material for gene expression analysis when tissue biopsy not feasible
Longitudinal patient monitoring using Parsortix showed reduction in CTCs with patient drug response providing further evidence to support the use of Parsortix in pharma services business
GUILDFORD, SURREY / ACCESSWIRE / September 20, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the Medical University of Innsbruck, Austria has published results from a study in metastatic prostate cancer (mPCa) patients …

Read the source article at Illinois Intelligencer
2021-09-20 07:04:38